Announcements Trials
Browse Landscape

Phase

Phase 2 61Phase 1/2 22Phase 1 18Phase EARLY_PHASE1 4Phase 3 3Phase 4 1Phase 2/3 1

Status

Recruiting 17Completed 5Active not recruiting 5Unknown 3Terminated 2Not yet recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Squamous Cell 1Head and Neck Neoplasms 1

Interventions

Oxaliplatin 5Leucovorin 5Fluorouracil 5Gemcitabine 4pirarubicin 2liposomal doxorubicin 2Surgical Procedures, Operative 2Radiation 2Paclitaxel 2Neoadjuvant Therapy 2Folfox protocol 2Capecitabine 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2vocimagene amiretrorepvec 1taxane 1sulindac sulfone 1remdesivir 1pembrolizumab 1nimotuzumab 1methylnaltrexone 1lenvatinib 1irinotecan sucrosofate 1carbon-11 acetate 1bavituximab 1alovudine 1aflibercept 1Thyroxine 1Therapeutics 1Temozolomide 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Withdrawn × pembrolizumab × Clear all
NCT06513884 2025-06-22

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Hookipa Biotech GmbH

Phase 2/3 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡